Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Lancet Oncol. 2022 Apr 12;23(5):659–670. doi: 10.1016/S1470-2045(22)00197-8

Figure 3.

Figure 3.

Overall survival in key subgroups of patients with MSI-H/dMMR mCRC. All subgroups were prespecified except for sex, ECOG performance status, and KRAS mutation. Prespecified categories were age, geographic region, recurrent versus new-diagnosed, BRAF wildtype vs BRAF V600E, site of primary tumor. The hazard ratios for death for the comparison of pembrolizumab versus standard-of-care therapy in all subgroups was calculated based on a Cox proportional regression model with Efron’s method of tie handling with treatment as a covariate. Two-sided interaction p-values are provided based on a multivariate Cox regression model with treatment, age, sex, ECOG performance status, geographic region, recurrent versus new-diagnosed, BRAF/KRAS/NRAS all wild type versus BRAF V600E, BRAF/KRAS/NRAS all wildtype versus KRAS or NRAS mutant, site of primary tumor and their interactions with treatment as covariates. The joint testing was done as a post-hoc exploratory analysis and P values are not adjusted for multiplicity and are nominal only. The dashed line indicates the overall OS HR for the study.